Position in PBYI
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$5,113,237
+$1,146,940 QoQ
Shares Held
800,194
+20.0% QoQ
Ownership
1.57%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 96%
Shared 0%
None 4%
Common Shares in PBYI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026AQR CAPITAL MANAGEMENT LLC holds $4,550,634,982 across 214 Biotechnology names. PBYI ranks #50 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,231,008 | $951,126,014 | |
| 2 | EXEL |
Exelixis, Inc.
|
13,095,741 | $561,676,326 | |
| 3 | INCY |
Incyte Corp
|
5,807,930 | $546,642,368 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
7,676,541 | $433,647,798 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
913,104 | $302,118,715 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
1,338,458 | $253,035,481 | |
| 7 | RPRX |
Royalty Pharma plc
|
3,782,038 | $181,424,357 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
5,946,858 | $164,727,963 |
All Filings in PBYI
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,113,237 | 800,194 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $3,966,297 | 666,605 | Shares | Other | 2026-02-17 | |
| 2025-09-30 | $693,866 | 130,672 | Shares | Other | 2025-11-14 | |
| 2025-06-30 | $486,280 | 141,773 | Shares | Other | 2025-08-14 | |
| 2025-03-31 | $149,354 | 50,458 | Shares | Other | 2025-05-15 | |
| 2024-12-31 | $32,990 | 10,817 | Shares | Other | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||